GlassScriptPhysician profile
Whitney P Haley
NPI 1053713685
$3,644.17
in general payments reported to CMS, 2019-2025
23 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $659 · 2023: $443 · 2024: $1,095 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.17 |
| Education | $117.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $777.90 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Genzyme Corporation | $482.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $330.88 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $276.27 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $265.75 | 2021-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $219.14 | 2021-2024 | Yupelri |
| Grifols USA, LLC | $213.23 | 2021-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $194.94 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $153.46 | 2021-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Axsome Therapeutics, INC. | $84.06 | 2022-2024 | Sunosi |
| Verona Pharma, INC. | $80.27 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $75.85 | 2025 | Yupelri |
| Insmed, INC. | $63.96 | 2025 | Brinsupri, Arikayce |
| Actelion Pharmaceuticals US, INC. | $58.21 | 2024-2025 | Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.75 | 2022-2024 | Tavneos, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $49.68 | 2023-2024 | Hyqvia |
| Electromed, INC. | $44.56 | 2024 | Smartvest |
| Inspire Medical Systems, INC. | $31.71 | 2025 | Inspire |
| Baxter Healthcare | $23.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.97 | 2022 | |
| 3b Medical, INC. | $21.34 | 2025 | Luna |
| Pfizer INC. | $17.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Haley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.